Product NewsLife Sciences
ELRIG research and innovation 2022: KREX proteomic analysis for biomarker discovery
7 Jun 2022
In this video, Sengenics describes the utility of autoantibodies (AAb) and discusses AAb technology. Watch to explore specific case studies for anti-drug antibody response with adalimumab, patient stratification in autoimmune diseases, some recent developments in Parkinson’s disease, and more.
About the company
Sengenics
Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, data-guided decision making. Our solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, therapeutic response prediction and development of companion diagnostics.
